Gonadotropin-Releasing Hormone and Its Analogues

GnRH secreted by the hypothalamus plays a key role in the regulation of the reproductive axis. Its normal pulsatile secretion is required for the pituitary release of FSH and LH hormones that regulate ovarian follicular activity. An intact multilevel feedback mechanism is required for normal function. Any disruption of this finely tuned endocrine axis results in abnormal ovarian function. GnRH analogues, agonists and antagonists, are now available and can be used to manage various clinical problems. GnRH analogues can be successfully used for the treatment of central precocious puberty, hormone-sensitive cancers, and various benign gynecologic conditions and play an important role in assisted reproduction. Their long-term use is not without side effects however; therefore future research has to focus on developing longer-acting formulas with proper add-back options that do not limit clinical efficacy but improve safety and allow long-term administration. Access this chapter Tax calculation will be finalised at checkout Purchases are for personal use only Similar content being viewed by others

Krsmanovic LZ, Hu L, Leung PK, Feng H, Catt KJ. The hypothalamic GnRH pulse generator: multiple regulatory mechanisms. Trends Endocrinol Metab. 2009 Oct;20(8):402–8. Knobil E. The neuroendocrine control of ovulation. Hum Reprod. 1988 May;3(4):469–72. Petersen SL, Ottem EN, Carpenter CD. Direct and indirect regulation of gonadotropin-releasing hormone neurons by estradiol. Biol Reprod. 2003;69:1771–8. Bakker J, Baum MJ. Neuroendocrine regulation of GnRH release in induced ovulators. Front Neuroendocrinol. 2000;21:220–62. Gamba M, Pralong FP. Control of GnRH neuronal activity by metabolic factors: the role of leptin and insulin. Mol Cell Endocrinol. 2006 Jul 25;254-255:133–9. Hu L, Gustofson RL, Feng H, Leung PK, Mores N, Krsmanovic LZ, et al. Converse regulatory functions of estrogen receptor-alpha and -beta subtypes expressed in hypothalamic gonadotropin-releasing hormone neurons. Mol Endocrinol. 2008 Oct;22(10):2250–9. Chappell PE, Levine JE. Stimulation of gonadotropin-releasing hormone surges by estrogen. I. Role of hypothalamic progesterone receptors. Endocrinology. 2000 Apr;141(4):1477–85. Schally AV, Kastin AJ. Stimulation and inhibition of fertility through hypothalamic agents. Drug Ther. 1971;1:29–32. Ortmann O, Weiss JM, Diedrich K. Gonadotrophin-releasing hormone (GnRH) and GnRH agonists: mechanisms of action. Reprod Biomed Online. 2002;5(Suppl 1):1–7. Li P, Li Y, Yang CL. Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty. A meta-analysis. Medicine. 2014;93:1–8. Heger S, Sippel WG, Partsch CJ. Gonadotropin-releasing hormone analogue treatmnt for precocious puberty. Twenty years of experience. Endocr Rev. 2005;8:94–125. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in precocious puberty. J Clin Endocrinol Metab. 1999 Jun;84(6):1973–8. Oostdijk W, Drop SL, Odink RJ, Hümmelink R, Partsch CJ, Sippell WG. Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German precocious puberty study group. Acta Paediatr Scand Suppl. 1991;372:39–45. Lee PA, Klein K, Mauras N, Neely EK, Bloch CA, Larsen L, et al. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty. J Clin Endocrinol Metab. 2012 May;97(5):1572–80. Xu X, Chen X, Hu H, Dailey AB, Taylor BD. Current opinion on the role of testosterone in the development of prostate cancer: a dynamic model. BMC Cancer. 2015 Oct 26;15:806. Shore ND, Abrahamsson PA, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013 Mar;16(1):7–15. Sharifi N, Gulley JL, Dahut WL. An update on androgen deprivation therapy for prostate cancer. Endocr Relat Cancer. 2010 Oct 29;17(4):R305–15. Vis AN, van der Sluis TM, Al-Itejawi HH, van Moorselaar RJ, Meuleman EJ. Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact? Urol Oncol. 2015 Jan;33(1):7–15. Tombal B, Miller K, Boccon-Gibod L, Schröder F, Shore N, Crawford ED, et al. Additional analysis of the secondary end point of biochemical recurrence rate in a phase 3 trial (CS21) comparing degarelix 80 mg versus leuprolide in prostate cancer patients segmented by baseline characteristics. Eur Urol. 2010 May;57(5):836–42. Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531–8. Cleator SJ, Ahamed E, Coombes RC, Palmieri C. A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer. 2009 Jun;9(Suppl 1):S6–S17. Tan SH, Wolff AC. The role of ovarian ablation in the adjuvant therapy of breast cancer. Curr Oncol Rep. 2008 Jan;10(1):27–37. Schmid P, Untch M, Wallwiener D, Kossé V, Bondar G, Vassiljev L, et al. TABLE-study (Takeda adjuvant breast cancer study with Leuprorelin acetate). Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study. Anticancer Res. 2002 Jul-Aug;22(4):2325–32. von Minckwitz G, Graf E, Geberth M, Eiermann W, Jonat W, Conrad B, et al. CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93). Eur J Cancer. 2006 Aug;42(12):1780–8. Goel S, Sharma R, Hamilton A, Beith J. LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women. Cochrane Database Syst Rev. 2009 Oct 7;4:CD004562. Castiglione-Gertsch M. Adjuvant treatment of breast cancer: sequence and duration of hormonal therapy. Ann Oncol. 2006 Sep;17(Suppl 10):x51–3. Gougeon A. Regulation of follicular ovarian development in primates: facts and hypothesis. Endocr Rev. 1996;17:121–55. The Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013;100:1214–23. Hickman LC, Valentine LN, Falcone T. Preservation of gonadal function in women undergoing chemotherapy: a review of the potential role for gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 2016 Oct;215(4):415–22. Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, et al. GIM study group. Ovarian suppression with Triptorelin during adjuvant breast cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015 Dec 22-29;314(24):2632–40. Moore HC, Unger JM, Phillips KA, Boyle F, Hitre E, Porter D. Et al; POEMS/S0230 investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015 Mar 5;372(10):923–32. Elgindy EA, El-Haieg DO, Khorshid OM, Ismail EI, Abdelgawad M, Sallam HN, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. Obstet Gynecol. 2013 Jan;121(1):78–86. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012 Feb 10;30(5):533–8. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. German breast group investigators. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011 Jun 10;29(17):2334–41. Del Mastro L, Ceppi M, Poggio F, Bighin C, Peccatori F, Demeestere I, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev. 2014 Jun;40(5):675–83. Blumenfeld Z, Evron A. Preserving fertility when choosing chemotherapy regimens - the role of gonadotropin-releasing hormone agonists. Expert Opin Pharmacother. 2015 May;16(7):1009–20. Vitek WS, Shayne M, Hoeger K, Han Y, Messing S, Fung C. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. Fertil Steril. 2014 Sep;102(3):808–15. Vercellini P, Viganò P, Somigliana E, Fedele L. Endometriosis: pathogenesis and treatment. Nat Rev Endocrinol. 2014 May;10(5):261–75. Granese R, Perino A, Calagna G, Saitta S, De Franciscis P, Colacurci N, et al. Gonadotrophin-releasing hormone analogue or dienogest plus estradiol valerate to prevent pain recurrence after laparoscopic surgery for endometriosis: a multi-center randomized trial. Acta Obstet Gynecol Scand. 2015 Jun;94(6):637–45. Morelli M, Rocca ML, Venturella R, Mocciaro R, Zullo F. Improvement in chronic pelvic pain after gonadotropin releasing hormone analogue (GnRH-a) administration in premenopausal women suffering from adenomyosis or endometriosis: a retrospective study. Gynecol Endocrinol. 2013 Apr;29(4):305–8. Ferrero S, Venturini PL, Gillott DJ, Remorgida V. Letrozole and norethisterone acetate versus letrozole and triptorelin in the treatment of endometriosis related pain symptoms: a randomized controlled trial. Reprod Biol Endocrinol. 2011 Jun 21;9:88. Bayoglu Tekin Y, Dilbaz B, Altinbas SK, Dilbaz S. Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogue. Fertil Steril. 2011 Feb;95(2):492–6. Sesti F, Capozzolo T, Pietropolli A, Marziali M, Bollea MR, Piccione E. Recurrence rate of endometrioma after laparoscopic cystectomy: a comparative randomized trial between post-operative hormonal suppression treatment or dietary therapy vs. placebo. Eur J Obstet Gynecol Reprod Biol. 2009 Nov;147(1):72–7. Bergqvist A, Bergh T, Hogström L, Mattsson S, Nordenskjöld F, Rasmussen C. Effects of triptorelin versus placebo on the symptoms of endometriosis. Fertil Steril. 1998 Apr;69(4):702–8. Brown J, Farquhar C. Endometriosis: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2014 Mar 10;3:CD009590. Zupi E, Marconi D, Sbracia M, Zullo F, De Vivo B, Exacustos C, et al. Add-back therapy in the treatment of endometriosis-associated pain. Fertil Steril. 2004 Nov;82(5):1303–8. Barnhart K, Dunsmoor-Su R, Coutifaris C. Effect of endometriosis on in vitro fertilization. Fertil Steril. 2002 Jun;77(6):1148–55. Hughes E, Brown J, Collins JJ, Farquhar C, Fedorkow DM, Vandekerckhove P. Ovulation suppression for endometriosis. Cochrane Database Syst Rev. 2007 Jul 18;3:CD000155. The Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility: a committee opinion. Fertil Fteril. 2012;98:591–8. Sallam HN, Garcia-Velasco JA, Dias S, Arici A. Long-term pituitary down-regulation before in vitro fertilization (IVF) for women with endometriosis. Cochrane Database Syst Rev. 2006 Jan 25;1:CD004635. Bulun SE. Uterine fibroids. N Engl J Med. 2013 Oct 3;369(14):1344–55. Islam MS, Protic O, Giannubilo SR, Toti P, Tranquilli AL, Petraglia F, et al. Uterine leiomyoma: available medical treatments and new possible therapeutic options. J Clin Endocrinol Metab. 2013 Mar;98(3):921–34. Chabbert-Buffet N, Esber N, Bouchard P. Fibroid growth and medical options for treatment. Fertil Steril. 2014 Sep;102(3):630–9. Friedman AJ, Harrison-Atlas D, Barbieri RL, Benacerraf B, Gleason R, Schiff I. A randomized, placebo-controlled, double-blind study evaluating the efficacy of leuprolide acetate depot in the treatment of uterine leiomyomata. Fertil Steril. 1989 Feb;51(2):251–6. Seracchioli R, Venturoli S, Colombo FM, Bagnoli A, Vianello F, Govoni F, et al. GnRH agonist treatment before total laparoscopic hysterectomy for large uteri. J Am Assoc Gynecol Laparosc. 2003 Aug;10(3):316–9. Crosignani PG, Vercellini P, Meschìa M, Oldani S, Bramante T. GnRH agonists before surgery for uterine leiomyomas. A review. J Reprod Med. 1996 Jun;41(6):415–21. Stovall TG, Muneyyirci-Delale O, Summitt RL Jr, Scialli AR. GnRH agonist and iron versus placebo and iron in the anemic patient before surgery for leiomyomas: a randomized controlled trial. Leuprolide acetate study group. Obstet Gynecol. 1995 Jul;86(1):65–71. Vercellini P, Trespìdi L, Zaina B, Vicentini S, Stellato G, Crosignani PG. Gonadotropin-releasing hormone agonist treatment before abdominal myomectomy: a controlled trial. Fertil Steril. 2003 Jun;79(6):1390–5. Chen I, Motan T, Kiddoo D. Gonadotropin-releasing hormone agonist in laparoscopic myomectomy: systematic review and meta-analysis of randomized controlled trials. J Minim Invasive Gynecol. 2011 May-Jun;18(3):303–9. de Ziegler D, Cedars MI, Randle D, Lu JK, Judd HL, Meldrum DR. Suppression of the ovary using a gonadotropin releasing-hormone agonist prior to stimulation for oocyte retrieval. Fertil Steril. 1987 Nov;48(5):807–10. Siristatidis CS, Gibreel A, Basios G, Maheshwari A, Bhattacharya S. Gonadotrophin-releasing hormone agonist protocols for pituitary suppression in assisted reproduction. Cochrane Database Syst Rev. 2015 Nov 9;11:CD006919. Albuquerque LE, Tso LO, Saconato H, Albuquerque MC, Macedo CR. Depot versus daily administration of gonadotrophin-releasing hormone agonist protocols for pituitary down regulation in assisted reproduction cycles. Cochrane Database Syst Rev. 2013 Jan 31;1:CD002808. Al-Inany HG, Youssef MA, Ayeleke RO, Brown J, Lam WS, Broekmans FJ. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev. 2016 Apr 29;4:CD001750. Xiao JS, Su CM, Zeng XT. Comparisons of GnRH antagonist versus GnRH agonist protocol in supposed normal ovarian responders undergoing IVF: a systematic review and meta-analysis. PLoS One. 2014 Sep 12;9(9):e106854. Tarlatzis BC, Fauser BC, Kolibianakis EM, Diedrich K, Rombauts L, Devroey P. GnRH antagonists in ovarian stimulation for IVF. Hum Reprod Update. 2006 Jul-Aug;12(4):333–40. Youssef MA, Van der Veen F, Al-Inany HG, Mochtar MH, Griesinger G, Nagi Mohesen M, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev. 2014 Oct 31;10:CD008046. Engmann L, Benadiva C, Humaidan P. GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis. Reprod Biomed Online. 2016 Mar;32(3):274–85. Martins WP, Ferriani RA, Navarro PA, Nastri CO. GnRH agonist during luteal phase in women undergoing assisted reproductive techniques: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2016 Feb;47(2):144–51. Summary GnRH secreted by the hypothalamus plays a key role in the regulation of the reproductive axis. Its normal pulsatile secretion is required for the pituitary release of FSH and LH hormones that regulate ovarian follicular activity. An intact multilevel feedback mechanism is required for normal function. Any disruption of this finely tuned endocrine axis results in abnormal ovarian function. GnRH analogues, agonists and antagonists, are now available and can be used to manage various clinical problems. GnRH analogues can be successfully used for the treatment of central precocious puberty, hormone-sensitive cancers, and various benign gynecologic conditions and play an important role in assisted reproduction. Their long-term use is not without side effects however; therefore future research has to focus on developing longer-acting formulas with proper add-back options that do not limit clinical efficacy but improve safety and allow long-term administration. Author information Authors and Affiliations Editor information Editors and Affiliations Rights and permissions Copyright information © 2020 Springer Nature Singapore Pte Ltd. About this chapter Cite this chapter Kovacs, P. (2020). Gonadotropin-Releasing Hormone and Its Analogues. In: Allahbadia, G.N., Ata, B., Lindheim, S.R., Woodward, B.J., Bhagavath, B. (eds) Textbook of Assisted Reproduction. Springer, Singapore. https://doi.org/10.1007/978-981-15-2377-9_8 Download citation DOI: https://doi.org/10.1007/978-981-15-2377-9_8 Published: Publisher Name: Springer, Singapore Print ISBN: 978-981-15-2376-2 Online ISBN: 978-981-15-2377-9 eBook Packages: MedicineMedicine (R0)